Sponsors & Exhibitors


Platinum Meeting Partners



Gold Circle Supporters


Scientific & Medical Information


Silver Circle Supporters




Essential Collaborator Supporters

Foundation Builder Supporters











HTRS 2021 Scientific Symposium (“HTRS 2021”) a completely virtual event, March 10-12, 2021, to safeguard the health of our attendees during the ongoing COVID-19 pandemic.

The HTRS 2021 Sponsorship & Exhibitor Prospectus has been revised for the virtual event, removing the in-person options, and promoting the opportunities available for the online format. 

HTRS has many exciting opportunities that are unique to a virtual platform:

  • Increased Satellite Symposia - 10 concurrent time slots and 1 exclusive lunchtime session pre- and post conference -- 2 remain for purchase. Satellite Symposia are always the fastest-selling sponsorship opportunity during HTRS meetings. Below is confirmed satellites per day: 

    • Wednesday, March 10, 2021

      • Pre-Symposium Concurrent Sessions, 12:00 PM - 1:00 PM ET:

        • CSL Behring

          • Session Title: On-Demand Bleed Resolution in Hemophilia B With an Extended Half-Life Factor IX Therapy
          • Speaker: Miguel Escobar, MD; Professor, University of Texas Health Science Center at Houston-McGovern Medical School
          • Overview: This educational symposium will focus on the current role of Factor IX replacement therapy for on-demand resolution of bleeding episodes in patients with hemophilia B and will review the clinical trial data for on-demand use of IDELVION. Audience members will learn about the features of this product that made it an attractive choice in this setting. Attendees will hear about a case study of a patient who switched to IDELVION for on-demand therapy from a different FIX replacement product.
        • Sanofi Genzyme

          • Session Title: "siRNA Technology in Hemophilia"
          • Speaker: Guy Young, MD, Director, Hemostasis and Thrombosis Program, Children's Hospital of LA; Professor of Pediatrics, Keck School of Medicine of USC
          • Overview: This presentation will cover small interfering RNA (siRNA) technology and its potential role in Hemophilia treatment.
      • Post-Symposium Concurrent Session, 5:30 PM  - 6:30 PM ET:

        • Takeda

          • Session Title: ADVATE® [Antihemophilic Factor (Recombinant)] Clinical Presentation
          • Speaker: Dr Tammuella Chrisentery Singleton, MD, Chief, Pediatric Hematology, Director, Hemophilia Treatment Center, Mississippi Center for Advanced Medicine (MCAM), Louisiana Center for Advanced Medicine (LCAM)
          • Overview: ADVATE® [Antihemophilic Factor (Recombinant)] clinical information review through the lens of a patient case: Meet James (hypothetical patient, for illustrative purposes only)
    • Thursday, March 11, 2021

      • Pre-Symposium Concurrent Sessions, 12:00 PM - 1:00 PM ET:

        • Bayer

          • Session Title: “Patient focused prophylaxis management for patients with hemophilia: a case-based discussion”
          • Speaker: Stacy Croteau, MD, MMS, Attending Physician, Boston Children’s Hospital, Medical Director, Boston Hemophilia Center, Assistant Professor of Pediatrics, Harvard Medical School
          • Overview: An interactive patient focused discussion on the importance of personalizing therapy with practical case studies based on real life clinical experience. The presentation will cover population PK models and available tools, benefits of integrating PK into hemophilia prophylaxis decision-making, how to generate PK profiles with population PK tools, and how provider and patient can best collaborate to set goals and decide on treatment plans.
        • Novo Nordisk

          • Session Title: A rFVIIa with over 30 years of experience with treating hemophilia and other rare bleeding disorders
          • Speakers:
            • Stephanie Seremetis, MD, Chief Medical Officer, GD Biopharm, Novo Nordisk Inc.

            • Miguel Escobar, MD, Medical Director, Gulf States Hemophilia and Thrombophilia Center, University of Texas Health Science Center, Houston

            • Joanna Davis, MD, Medical Director, Pediatric Hemophilia Treatment Center, University of Miami Health System, Florida

          • Overview: Learn about the only rFVIIa approved for use in a wide range of indications in rare bleeding disorders including patients with congenital hemophilia with inhibitors of all ages, acquired hemophilia, Glanzmann's thrombasthenia, and congenital factor VII deficiency, through patient case reports.

      • Exclusive Session, 2:10 PM - 3:10 PM ET:

        • Genentech 

          • Session Title: SubQ Prophylaxis for Hemophilia A: 3 Experts Discuss the Latest Data From the Pivotal Trials 
          • Speakers
            • Amy Shapiro, MD, Indiana Hemophilia and Thrombosis Center, Inc.
            • Michael Callaghan, MD, Wayne State University School of Medicine Children's Hospital of Michigan
            • Guy Young, MD, University of Southern California Children's Hospital, Los Angeles
          • Overview: Join Drs. Amy Shapiro, Michael Callaghan, and Guy Young as they discuss subcutaneous prophylaxis for hemophilia A, their perceptions of the latest pivotal trial data, and how they have evolved their management of hemophilia A patients throughout the pandemic. This program will be presented live, with an opportunity to ask questions throughout the presentation. This promotional symposium is sponsored by Genentech, Inc.
      • Post-Symposium Concurrent Session, 6:15 PM - 7:15 PM ET:

        • Takeda/PER - CME

          • Session Title: Putting the Patient First: Individualized Strategies for the Treatment and Management of von Willebrand Disease
          • Speakers
            • Jonathan C. Roberts, MD, Associate Medical Director, Associate Research Director, Bleeding & Clotting Disorders Institute, Assistant Professor of Pediatrics, University of Illinois College of Medicine, Peoria, IL

            • Robert F. Sidonio, Jr., MD, MSc, Pediatric Hematologist, Medical Director of Hemophilia, Aflac Cancer & Blood Disorders Center, Children’s Healthcare of Atlanta, Associate Professor of Pediatrics, Emory University School of Medicine, Atlanta, GA

            • Angela C. Weyand, Assistant Professor of Pediatrics, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, MI

          • Overview: Although the clinical management of von Willebrand Disease (VWD) has evolved over the past few decades, it continues to pose a therapeutic challenge. There is currently no cure for VWD; however, there are safe and effective treatments for all known types of this disease. Ensuring that clinicians who treat this condition maintain knowledge that is at the forefront of clinical decision-making is critical to promoting optimized patient outcomes.

            This symposium features expert clinician-researcher faculty who will share data regarding the mechanistic activity, efficacy, and safety of therapeutic strategies that target VWD pathophysiology. Furthermore, the faculty will use in-depth, case-based discussion to share best practices for selecting therapy for patients with Type 1, 2, and 3 VWD.

        • Novo Nordisk

          • Session Title: Double Feature:  Obesity in Hemophilia and a Treatment Option for Hemophilia A
          • Speakers
            • Stephanie Seremetis, MD, Chief Medical Officer, GD Biopharm, Novo Nordisk Inc.

            • Meera B. Chitlur, MD, Professor of Pediatrics, Central Michigan University School of Medicine, Pediatric Hematologist/Oncologist, Children’s Hospital of Michigan

            • Doris Quon, MD, PhD, Medical Director, Orthopaedic Hemophilia Treatment Center, Orthopaedic Institute for Children, University of California, Los Angeles

            • Anthony Auriemma, MD, JD, Medical Director, The Center for Health and Nutrition

          • Overview: The first part is an interactive program discussing the importance of managing obesity in the hemophilia community.  Managing obesity is generally one of the toughest challenges for health care professionals and is often overlooked.  This program will feature a discussion on obesity as a disease and how obesity impacts people with hemophilia.  Results from a study designed to understand the barriers to initiating and maintaining weight loss in obese patients with hemophilia and to identify insights on the unique challenges of these patients from the perspective of health care professionals will be covered.

            In the second part, the program will feature aspects of the pathfinder clinical trial program and information on a factor VIII extended half-life product.

            The program is sponsored by Novo Nordisk and is being moderated by Dr. Stephanie Seremetis and will feature Dr. Meera Chitlur, Dr. Doris Quon and Dr. Anthony Auriemma.

    • Friday, March 12, 2021

      • Pre-Symposium Concurrent Sessions, 12:00 PM - 1:00 PM ET:

        • Alnylam Pharmaceuticals

          • Session Title: Introduction to GIVLAARI® (givosiran) for the Treatment of Adults with Acute Hepatic Porphyria - Featuring 18-month data from the ENVISION Open-Label Extension (OLE) Study
          • Speaker: Dr. Appalanaidu Sasapu, MD
          • Overview: Join Alnylam Pharmaceuticals for a presentation featuring the latest information on GIVLAARI, an RNA interference (RNAi) therapeutic for the treatment of adults with Acute Hepatic Porphyria (AHP). AHP is a rare, genetic disease characterized by debilitating, potentially life-threatening attacks. The cardinal symptom of an AHP attack is severe, diffuse abdominal pain. 

            GIVLAARI is indicated for the treatment of adults with acute hepatic porphyria (AHP). GIVLAARI is contraindicated in patients with known severe hypersensitivity to givosiran. Reactions have included anaphylaxis. Additional Important Safety Information about GIVLAARI, including Contraindications, Warnings & Precautions for Anaphylactic Reaction, Hepatic Toxicity, and Injection Site Reactions can be found through these links to Important Safety Information and to the full Prescribing Information.

            Led by Dr. Appalanaidu Sasapu, this session will feature results from the 18-month analysis from the ENVISION ongoing open-label extension (OLE) study, as well as a range of topics including:
            •    AHP Disease overview and pathophysiology
            •    Introduction to GIVLAARI
            •    Mechanism of action for GIVLAARI
            •    Efficacy and safety results from the ENVISION study 

        • Sanofi Genzyme

          • Session Title: "A Breakthrough in aTTP Treatment: Now recommended by the ISTH Guidelines"
          • Speaker: Dr. Jay Raval, Associate Professor and Senior Director of Transfusion Medicine and Therapeutic Pathology, University of New Mexico
          • Overview: The program will provide an overview of acquired thrombotic thrombocytopenic purpura (aTTP) – a rare, life-threatening, auto-immune disease - and the urgency for rapid diagnosis and treatment. The program will then review the recently published ISTH Guidelines on the diagnosis and treatment of aTTP with a focus on the first and only FDA-approved therapy indicated for adults with aTTP.
  • HTRS Leadership / Key Opinion Leaders (KOL) Meetings - 4 options are available -- 2 remain for purchase -- for 30-minute meetings with HTRS leaders and volunteers who are key opinion leaders in the industry. This face-to-face time will only include these leaders and your company registrants. Bundle this opportunity with another sponsorship item to maximize your visibility for your esteemed colleagues in the hemostasis and thrombosis community.

  • Exhibitor Speed Breaks - HTRS is dedicated to making connections and increasing networking opportunities for exhibitors by offering face-to-face “speed meetings.” These sessions will increase the amount of time you are in front of HTRS 2021 attendees while adding value to your exhibition. 

Your company’s sponsorship and/or exhibit will help assure the success of the HTRS 2021 Scientific Symposium regardless of format. We hope you will be well represented during the meeting.

Interested in multiple opportunities? Please reach out to HTRS meeting management at contact@htrs2021.org or call +1 856.471.7211 to discuss customizing your own package that meets your company's marketing needs and maximizes your exposure.

Please Note: All sponsorship and exhibitor booths are offered on a first-come, first-served basis and are not confirmed until payment is received.

Thanks to your support, HTRS is able to offer the Symposium, secure key faculty and speakers, provide publishing fund support for authors of distinguished abstracts, host vital HTRS programs, and aid the overall operation of HTRS as a non-profit 501c3 organization. Sponsors help fulfill the society’s mission to advance research, mentoring, workforce development, and continuing medical education for physicians, investigators, and all health care professionals interested in advancing care for people with hemostatic and thrombotic disorders.